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Abstract
Introduction Policy interventions to address inappropriate
prescribing of antipsychotic drugs to older people diag-
nosed with dementia are commonplace. In the UK, warn-
ings were issued by the Medicines Healthcare products
Regulatory Agency in 2004, 2009 and 2012 and the
National Institute for Health and Care Excellence guidance
was published in 2006. It is important to evaluate the
impact of such interventions.
Methods We analysed routinely collected primary-care
data from 111,346 patients attending one of 689 general
practices contributing to the Clinical Practice Research
Datalink to describe the temporal changes in the pre-
scribing of antipsychotic drugs to patients aged 65 years
or over diagnosed with dementia without a concomitant
psychosis diagnosis from 2001 to 2014 using an
interrupted time series and a before-and-after design.
Logistic regression methods were used to quantify the
impact of patient and practice level variables on pre-
scribing prevalence.
Results Prescribing of first-generation antipsychotic drugs
reduced from 8.9% in 2001 to 1.4% in 2014 (prevalence
ratio 2014/2001 adjusted for age, sex and clustering within
practices (0.14, 95% confidence interval 0.12–0.16),
whereas there was little change for second-generation
antipsychotic drugs (1.01, confidence interval 0.94–1.17).
Between 2004 and 2012, several policy interventions
coincided with a pattern of ups and downs, whereas the
2006 National Institute for Health and Care Excellence
guidance was followed by a gradual longer term reduction.
Since 2013, the decreasing trend in second-generation
antipsychotic drug prescribing has plateaued largely driven
by the increasing prescribing of risperidone.
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Conclusions Increased surveillance and evaluation of drug
safety warnings and guidance are needed to improve the
impact of future interventions.
Key Points
A Medicines Healthcare products Regulatory
Agency drug safety warning in 2004 was associated
with a marked short-term reduction in the
prescribing of second-generation antipsychotic drugs
to older patients with dementia, whereas subsequent
Medicines Healthcare products Regulatory Agency
warnings had little impact.
National Institute for Health and Care Excellence
guidance published in 2006 was followed by a
longer-term declining trend but was not temporally
associated with an immediate reduction in
prescribing.
Prescribing first-generation antipsychotic drugs to
older patients with dementia without psychosis
occurred much less frequently in 2014 than 2001 but
prescribing of second-generation antipsychotic drugs
remained similar.
A further, carefully worded, warning may be justified
to reduce the longer-term prescribing of second-
generation antipsychotic drugs to patients with
dementia.
1 Introduction
The risks of prescribing antipsychotic drugs to patients
with dementia have been well documented [1–4].
Antipsychotic drugs may cause extrapyramidal side effects
[5] and studies have shown that the newer second-gener-
ation atypical antipsychotic drugs are also associated with
an increased risk of stroke [1, 6–9]. Regulatory bodies in
several countries have issued warnings, guidance and
advice aiming to reduce inappropriate prescribing of
antipsychotic drugs to patients diagnosed with dementia
[10–21]. It is important to evaluate the impact, and com-
pare the methods of dissemination, of such interventions to
inform future policy to reduce antipsychotic drug pre-
scribing to patients with dementia as well as provide useful
lessons on implementing national guidance and warnings.
In the UK, there have been several consecutive warnings
and guidance aiming to reduce inappropriate prescribing of
antipsychotic drugs to patients diagnosed with dementia
(Table 1). During March 2004, the Committee for the
Safety of Medicines (CSM) warned through a personal
letter to all healthcare professionals marked ‘urgent’ that
risperidone or olanzapine should not be used for the
treatment of behavioural symptoms of dementia in older
people because of a clearly documented increased risk of
stroke [10]. Later studies, however, showed that similar
risks existed for other second-generation antipsychotic
drugs and indeed for first-generation antipsychotic drugs
[8]. Guidelines published by the National Institute for
Health and Care Excellence (NICE) in November 2006
recommended that antipsychotic drugs should not be pre-
scribed for patients who experience behavioural and psy-
chological symptoms of dementia of mild-to-moderate
severity because of the increased risk of cerebrovascular
adverse effects. This guideline stated that an antipsychotic
drug should only be considered for patients with dementia
with severe behavioural and psychological symptoms
(psychosis and/or agitated behaviour causing significant
distress), and only after other approaches have proved
inadequate and the risks considered and discussed with the
patient and/or their carers. Additionally, the prescription
should be time limited and reviewed according to clinical
need or every 3 months [11]. There is no legal obligation to
follow NICE guidelines but their implementation is
actively encouraged in England and Wales [12]. The
approach to the implementation of NICE guidance varies
between National Health Service organisations.
Following a 2008 review by the European Medicines
Agency that aimed to harmonise the Summary of Product
Characteristics for Risperdal (risperidone) [13], the UK
Medicines Healthcare products Regulatory Agency
(MHRA) released a drug safety update (DSU) in March
2009 stating that risperidone was licenced for the short-
term (\6 weeks) treatment of severe aggression in people
with Alzheimer’s disease. At the same time, risperidone
was added to the MHRA’s Black Triangle list of medici-
nes, indicating the start of intensive safety monitoring [14].
In June 2009, a further MHRA DSU reminded of the
possible risks [15]. Drug safety updates are online e-bul-
letins published monthly on the UK Government website.
Healthcare professionals can sign up to receive an email
alert when the monthly update is published (http://www.
medsiq.org/tool/drug-safety-update).
In October 2009, a review commissioned by the English
Department of Health called for urgent action [16]. The
report estimated that up to two-thirds of prescriptions of
antipsychotic drugs to patients with dementia were
unnecessary and potentially harmful. Following the report,
the UK government pledged to reduce the use of antipsy-
chotic drugs for people with dementia [17]. However, in
May 2012, a MHRA DSU noted that, despite an encour-
aging overall reduction in the proportion of elderly people
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with dementia being prescribed antipsychotic drugs since
2007, the reductions fell short of the hoped-for levels [18].
The UK government has continued to place a high priority
on reducing the inappropriate prescribing of antipsychotic
drugs for people with dementia; the Prime Minister laun-
ched a national challenge to fight dementia in March 2012
followed by the ‘Challenge on Dementia 2020’ in 2015
[17, 19]. Reducing inappropriate prescribing of antipsy-
chotic drugs to patients with dementia is a specified aim in
this national initiative. A recent study estimated that
around 8% of patients aged 65 years or over with a
dementia diagnosis received a potentially inappropriate
prescription for an antipsychotic drug [22].
The impact of these UK interventions aiming to reduce
the inappropriate prescribing of antipsychotic drugs to
older people with dementia has been investigated in
Scottish and UK general practice [23–26]. Both studies
found that the 2004 warning was associated with an
immediate but short-term reduction in antipsychotic drug
prescribing, whereas the 2009 intervention was not asso-
ciated with an immediate reduction but was followed by a
declining trend in antipsychotic drug prescribing. Fur-
thermore, both studies highlighted that the 2004 decline
was driven largely by a reduction in the prescribing of
risperidone and olanzapine, but there was a subsequent
increase in the prescribing of quetiapine [24]. Another
interrupted time series (ITS) study of the prescribing of
second-generation antipsychotic drugs in one National
Health Service Hospital Foundation Trust also found a
decline following the 2004 warning and increasing use of
risperidone following the 2009 warning [27]. Further-
more, a national audit observed a decline in the pre-
scribing of antipsychotic drugs to patients with dementia
from 1995 to 2011, [18] subsequently confirmed by a
more recent study using anonymised primary care data
[28]. These studies [18, 28] considered overall
Table 1 Definition of dates for interrupted time series (ITS) analysis and before and after comparison of UK national interventions aiming to
reduce the inappropriate prescribing of antipsychotic drugs to patients with dementia
Dates Intervention period Time periods for ITS
analysis: 1. before
intervention
2. During intervention
3. After intervention
Audit dates for before (1)
and after comparison (2)
March
2004
MHRA Committee for the Safety of Medicines warning: risperidone and
olanzapine should not be used to treat behavioural symptoms of
dementia in older patients
1. March 2003 to February
2004
2. March 2004 to June
2004
3. July 2004 to June 2005
1. 1 March, 2004
2. 1 September 2004
November
2006
NICE guidelines: antipsychotic drugs should only be used for severe
cognitive symptoms for a limited time after other approaches have
proved inadequate
1. November 2005 to
October 2006
2. November 2006 to
February 2007
3. March 2007 to February
2008
1. 1 November, 2006
2. 1 May, 2007
March
2009
MHRA drug safety update: risperidone licenced for severe aggression in
patients with Alzheimer’s disease and added to the MHRA’s Black
Triangle list of medicines
1. March 2008 to February
2009
2. March 2009 to February
2010
3. March 2010 to February
2011
1. 1 March, 2009
2. 1 May, 2010
June 2009 Report on yellow card results and reiteration of the risks of antipsychotic
drug use
October
2009
Expert review called for urgent action
November
2009
UK government pledge to reduce the use of antipsychotic drugs for
patients with dementia
March
2012
Prime minister launches the National Dementia Challenge 1. March 2011 to February
2012
2. March 2012 to August
2012
3. September 2012 to
August 2013
1. 1 March, 2012
2. 1 November, 2012
MHRA Medicines Healthcare products Regulatory Agency, NICE National Institute for Health and Care Excellence
Drug Safety Warnings and Antipsychotic Drug Prescribing to Patients with Dementia
antipsychotic drug prescribing but did not consider dif-
ferent classes or specific antipsychotic drugs in detail.
The prescribing of antipsychotic drugs to patients with
dementia in Italy, USA and Canada has also been exam-
ined in the context of policy interventions. In Italy, a
similar warning to the 2004 CSM warning coincided with a
short-lived reduction in antipsychotic drug prescribing,
particularly second generation, but from 2009 there was an
increasing trend for both classes of antipsychotic drug [26].
During 2005, the US Food and Drug Administration issued
a warning concerning the use of atypical antipsychotic
drugs in dementia that was found to be associated with a
reduction in prescribing recorded in the national Veterans
Affairs dataset [20]. A Canadian study found a deceleration
in the growth of atypical antipsychotic drug use among
patients with dementia, but no overall reduction in pre-
scribing [21].
These policy interventions aim to reduce inappropriate
prescribing rather than simply reduce prescribing, thus it is
important to use clinically meaningful measures. Previ-
ously, we have used prescribing safety indicators to address
potentially inappropriate prescribing [22, 29]. In this study,
we have used a prescribing safety indicator (PSI) that
specifically addresses the prescribing of antipsychotic
drugs to patients with dementia using anonymised, patient-
level electronic health records from the Clinical Practice
Research Datalink (CPRD) [30] to investigate the changes
in prescribing in the context of these policy interventions.
Our aims were to: (1) examine changes in the prevalence of
repeated prescribing of antipsychotic drugs (for at least
3 months) to patients aged 65 years or over diagnosed with
dementia and without a psychosis diagnosis from 2001 to
2014; (2) compare the proportion of older people with
dementia without a psychosis diagnosis prescribed a
repeated antipsychotic drug before and after the policy
interventions (warnings, updates, guidelines, reports)
described above; (3) analyse the changes in monthly pre-
scribing of antipsychotic drugs to older patients with
dementia without a psychosis diagnosis before, during and
after the interventions using an ITS design; and (4)
examine the patient- and practice-level predictors of pre-
scribing antipsychotic drugs to patients aged 65 years or
over with dementia without a psychosis diagnosis and the
variability between practices.
2 Methods
2.1 Population and Coding of Diagnoses
and Prescriptions
The CPRD is a primary care database of anonymised elec-
tronic health records from general practice that includes
around 7% of the UK population and is broadly representa-
tive of the UK population in terms of age, sex and ethnicity
[30]. All patients aged 65 years or over (defined by the year
when they turned 66) registered with one of the CPRD
practices between 1 January, 2001 and 31 December, 2014
that had uploaded data of research quality on or after the audit
date were included in the analysis. Patients were only
included from the time they registered with a CPRD practice
but their relevant diagnoses (dementia and psychosis) could
have been recorded before their most recent registration date
as their records would have been transferred from their
previous practice. Patients were categorised according to
codes recorded in their primary care record describing the
diagnosis of dementia or psychosis and the prescribing of
antipsychotic drugs as described elsewhere [22]. A full list of
codes to describe the diagnoses of dementia, psychosis and
antipsychotic drugs prescribed is provided in Electronic
Supplementary Material 1 and has been uploaded to https://
clinicalcodes.rss.mhs.man.ac.uk/medcodes/article/53/ [31].
2.2 Cross-Sectional Estimates of the Prevalence
of Potentially Inappropriate Prescribing
of Antipsychotic Drugs
The proportion of patients diagnosed with dementia and
without a psychosis diagnosis who were prescribed an
antipsychotic drug was estimated using a PSI as described
previously [22]. The PSI denominator included all patients
aged 65 years or over with dementia without a psychosis
diagnosis 6 months prior to an audit date. The PSI
numerator included all patients prescribed an antipsychotic
drug (by class and specific antipsychotic drug) at least
twice during the 6 months leading up to an audit date and
with at least 3 months between the first and last prescrip-
tion. The associations between patient and practice level
predictors and the prevalence of the PSI with an audit date
of 31 December, 2014 was estimated using a mixed-ef-
fects, two-level logistic regression model with random
effects at the practice level (i.e., patients nested within
practices) in Stata Version 14 (StataCorp, College Station,
Texas, USA). The practice-level predictors were list size,
practice location by region, index of multiple deprivation
quintile and the proportion of patients aged 65 years or
older registered at the practice (practices with a higher
proportion of older patients are more likely to be providers
of care for residential homes). Patient-level predictors were
age, sex and polypharmacy; polypharmacy was defined as
the number of drugs with at least two prescriptions of the
same drug on different dates (excluding antipsychotic
drugs) within the 12 months leading up to the audit date.
The heterogeneity between practices for the PSI was
quantified by the 95% prediction intervals derived from the
model with 95% confidence as described elsewhere [32].
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2.3 Longitudinal Changes in Prescribing
in the Context of Warnings and Guidance
Using two different approaches, we investigated temporal
changes in prescribing. First, a series of consecutive cross-
sectional analyses were undertaken using the PSI method
described above with a 6-monthly rolling time window of
audit dates from 2001 to 2014 (Fig. 1). To specifically
investigate the change in the prevalence of the PSI fol-
lowing the interventions, two audit dates covering the
6 months leading up to, and following, the date of the
intervention(s) were compared as a prevalence ratio
(Table 1). This before-and-after analysis used the two-level
logistic regression model described above that also inclu-
ded a categorical variable coding for the time periods
before and after the interventions (Table 1). This analysis
allows for the clinically appropriate short-term prescribing,
as described in the 2006 NICE guidelines [11], by
excluding prescribing occurring for less than 3 months
from the numerator and for ‘end of life’ prescribing by
excluding patients who died within the 6 months leading
up to the audit date from the denominator. However, it does
not take into account the pre- and post-intervention trends.
Therefore, a second approach used an ITS design, which
accounts for trends, to compare monthly changes in pre-
scribing within consecutive time periods. The time periods
were defined prospective to the analysis with respect to the
interventions described in Sect. 1 (Table 1) and repre-
sented the time 12 months before, the month of the inter-
vention, and the following 3 months (during period) and
12 months after each intervention. The ‘during’ period was
to allow time for the information to be disseminated to
practices and actioned. When interventions occurred clo-
sely in time, all interventions were included in the ‘during’
period. The period of 12 months before and after the
intervention was judged to provided sufficient observation
points to measure the secular time trend and minimise the
effect of seasonality (e.g., holidays). However, keeping the
time periods temporally close to the intervention reduces
potential confounding by events occurring at a more distant
time. Sensitivity analyses repeating these longitudinal
analyses using a cohort of all patients with dementia (in-
cluding those with a psychosis diagnosis) and descriptive
analyses of the temporal changes in the study population
are described in Electronic Supplementary Material 2.
For the ITS analysis, one prescription was sufficient for
inclusion in the numerator, rather than two prescriptions at
least 3 months apart as described for the PSI analyses. This
ensured no overlap between the time periods of observa-
tion, a prerequisite for ITS. The statistical comparison
between trends in monthly prescribing in different time
periods took the autocorrelation of the residuals into
Fig. 1 Prevalence of prescribing repeated antipsychotic drugs to
older patients diagnosed with dementia and without a psychosis
diagnosis during the 6 months leading up to the audit date alongside
the dates of interventions. Dashed lines indicate prevalence for all
patients with dementia (with or without a psychosis diagnosis)
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account by using an autoregressive, integrated moving
average model with a lag of 1 month [33]. In addition,
ordinary least-squares regression was used to estimate the
temporal trends before, during and after the interventions
with Newey–West standard errors to handle autocorrela-
tion. The ITS used the itsa command in Stata but the two-
level version of the model could not be used as some
practices did not contribute to the CPRD continuously from
2003 to 2013, thereby creating an unbalanced data
structure.
3 Results
Data from 111,346 patients aged 65 years or older with a
diagnosis of dementia and without psychosis, attending 689
UK general practices contributing data to the CPRD for at
least 6 months between 1 January, 2001 and 31 December,
2014, were analysed (median number of practices included
per year 573; range 459–601). The temporal changes in the
study population from 2001 to 2014 are described in
Electronic Supplementary Material 2.
3.1 Temporal Changes in Prescribing
of Antipsychotic Drugs from 2001 to 2014
Figure 1 shows the proportion of patients prescribed
antipsychotic drugs at least twice with at least 3 months
between the first and last prescription during the 6 months
leading up to an audit date (numerator) out of all patients
aged 65 years or over diagnosed with dementia, with or
without a psychosis diagnosis (denominator), alongside the
dates of the warnings and advice (Table 1). From 2001 to
2014, the observed proportion of patients receiving repe-
ated prescriptions for an antipsychotic drug fell from 15.8
to 8.2%. The majority of the reduction was the result of
decreased prescribing of first-generation antipsychotic
drugs, which fell from 8.9 to 1.4%. The opposite was
observed for second-generation antipsychotic drugs where
the observed proportion was similar in 2001 at 6.6% and
2014 at 6.9%. The corresponding prevalence ratios for
repeated prescribing at audit date 1 June, 2014 relative to 1
June, 2001 from the two-level logistic regression model
with random effects at the practice level and adjusted for
age and sex were 0.48 (95% CI 0.44–0.52) for all
antipsychotic drugs; 1.01 (95% CI 0.94–1.17) for second-
generation antipsychotic drugs and 0.14 (95% CI
0.12–0.16) for first-generation antipsychotic drugs. During
2003 and 2007–8, however, the observed repeated pre-
scribing prevalence of second-generation antipsychotic
drugs peaked at around 18%, significantly higher than the
2014 prevalence [prevalence ratio for audit date 1 June,
2014 adjusted for age and sex relative to (1) 1 January,
2004: 0.38, 0.36–0.41; and (2) 1 January, 2008: 0.41,
0.38–0.43]. The results from the dementia cohort without
excluding patients with a psychosis diagnosis (sensitivity
analysis) closely agreed with the results from the main
analysis (dashed lines in Fig. 1). The estimates of the
monthly change in prescribing of at least one antipsychotic
drug before, during and after each intervention are shown
in Table 2 alongside the p values comparing the monthly
change before the intervention to during and after the
intervention (the ITS analysis). Plots depicting the ITS
analysis (corresponding to Table 2) are shown for all
antipsychotic drugs in Fig. 2 and according to the class and
specific drug in Electronic Supplementary Material 3.
Table 2 also shows the estimates of the change in preva-
lence of repeated prescribing during the 6 months before
and after each intervention as prevalence ratios.
3.2 Temporal Changes in the Context of Policy
Interventions
During the 6 months following the 2004 CSM warning,
there was a marked decline in the prevalence of repeated
prescribing of second-generation antipsychotic drugs (0.66;
0.61–0.71, Table 2) and an increase for first-generation
antipsychotic drugs (1.17; 1.03–1.31, Table 2). The decline
in prescribing of second-generation antipsychotic drugs
was driven mainly by reductions in prescribing of risperi-
done and olanzapine but was attenuated by an increase in
the prescribing of quetiapine and amisulpride (see Panel A,
Electronic Supplementary Material 3). The pre-warning
increasing trend in monthly prescribing of second-genera-
tion antipsychotic drugs flattened following the warning,
whereas the pre-warning decreasing trend for first-genera-
tion antipsychotic drugs reversed to a post-warning
increasing trend (see Panel A, Electronic Supplementary
Material 3). Between the 2004 CSM warning and the 2006
NICE guidance, the prescribing trends had returned to the
pre-CSM direction (i.e., increasing second generation and
decreasing first generation, see Panel B, Electronic Sup-
plementary Material 3). There were no significant changes
in prescribing during or immediately following the 2006
NICE guidelines or in the prevalence of repeated pre-
scribing during the 6 months following the publication of
the guidelines (Table 2). The prescribing of second-gen-
eration antipsychotic drugs plateaued during 2007 and
2008, over a year after the publication of the 2006 NICE
guidance (Fig. 1), then began to decline.
Around the same time, the prescribing of first-gener-
ation antipsychotic drugs began to decline more steeply.
Prior to the series of interventions during 2009 (MHRA
DSU: March and June; expert review: October;
Government pledge: November) (Table 1), there was a
consistent declining trend in prescribing for both classes
S. J. Stocks et al.
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of antipsychotic drug that steepened for second-genera-
tion antipsychotic drugs (see Panel C, Electronic Sup-
plementary Material 3) but this was not significant
(Table 2). An increasing trend in risperidone prescribing
commenced around February 2010, approximately
11 months after the March 2009 DSU stated it was
licensed for short-term use (see Panel C, Electronic
Supplementary Material 3). The decline in prevalence
for risperidone even though there is a post-intervention
increasing trend (Table 2) reflects the a priori selection
of the time periods (Table 1). Following the March 2012
National Dementia Challenge and May 2012 MHRA
DSU, the decreasing trend in prescribing of second-
generation antipsychotic drugs including olanzapine,
quetiapine and amisulpride began to plateau but
risperidone continued along an upward trajectory (see
Panel D, Electronic Supplementary Material 3). During
2013, the downward trend in prescribing second-gener-
ation antipsychotic drugs plateaued driven largely by the
increasing trend for risperidone prescribing (see Fig. 1
and Panel D in Electronic Supplementary Material 3).
The autoregressive, integrated moving average model
predicted that 7.2% of patients were prescribed a second-
generation antipsychotic drug during January 2013,
which remained similar over the next 2 years (the pre-
dicted monthly change from January 2013 to December
2014 was -0.01% (-0.01 to 0.00%).
3.3 Cross-Sectional Analysis of Repeated
Antipsychotic Prescribing between June
and December 2014
The prevalence of patients with a diagnosis of dementia but
not psychosis and a repeated prescription for an antipsy-
chotic drug by patient and practice characteristics, as well
as unadjusted and adjusted odds ratios derived from the
multilevel mixed effects logistic regression model are
shown in Table 3. The variation in prescribing between
practices was high (see Figure C, Electronic Supplemen-
tary Material 2); the adjusted prediction intervals (expected
range of prevalence for a new practice joining the analysis)
for the time period January to June 2014 were 2.5–17.3%.
In the 6 months leading up to 30 June, 2014 younger
patients (aged 65–75 years) and those taking multiple
medications were more likely to be prescribed antipsy-
chotic drugs (Table 3). None of the practice-level variables
or sex significantly affected the likelihood of being pre-
scribed repeated antipsychotic drugs (list size, proportion
of patients aged 65 years or over, index of multiple
deprivation based on the practice postcode, Table 3). There
were some differences between geographical regions of the
UK with prescribing in Wales and Northern Ireland being
more frequent than regions in the south of England.T
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Drug Safety Warnings and Antipsychotic Drug Prescribing to Patients with Dementia
4 Discussion
Our most important finding is that the prescribing of first-
generation antipsychotic drugs to older patients diagnosed
with dementia and without a psychosis diagnosis declined
substantially between 2001 and 2014. The frequency of
prescribing second-generation antipsychotic drugs, how-
ever, despite a pattern of ups and downs, was essentially
the same in 2014 as in 2001. Since 2013, the declining
trend in second-generation antipsychotic prescribing has
been halted, driven almost exclusively by the increasing
prescribing of risperidone.
4.1 Prescribing Patterns in the Context of National
Guidelines and Drug Safety Warnings
Fluctuations in the prevalence of prescribing antipsychotic
drugs and switching between classes and specific antipsy-
chotic drugs were generally consistent with clinicians
responding to national guidelines and drug safety warnings.
The most noticeable change in prescribing, however, did
not temporally coincide with any specific policy interven-
tion. This was a plateauing of the increasing trend for
second-generation antipsychotic drugs towards the end of
2007 and the commencement of a decreasing trend during
2008. The most recent preceding intervention was the
publication of the 2006 NICE guidance and possibly this
had a more gradual and long-term impact compared with
the earlier 2004 CSM warning.
The large changes in prescribing coinciding with the
2004 CSM warning suggest that this type of direct warning
can persuade clinicians to change their prescribing habits
and place a responsibility on the issuer to ensure that the
warning does not have unintended consequences. For
example, specifying risperidone and olanzapine in the
warning may have precipitated the increased prescribing of
first-generation antipsychotic drugs as well as quetiapine
and amisulpride. Similarly, specifying risperidone in the
March 2009 DSU was followed by an increase in its pre-
scribing some months later. Some increase in monthly
Fig. 2 Interrupted time series analyses for monthly prescribing of antipsychotic drugs to older patients diagnosed with dementia and without a
psychosis diagnosis; boundary points defined according to warnings and guidance described in Table 1
S. J. Stocks et al.
Table 3 Prevalence of patients with dementia without a psychosis
diagnosis receiving repeated antipsychotic drug prescriptions between
1 January, and 30 June, 2014 and unadjusted and adjusted odds ratios
from a two-level logistic regression model with random effects at the
practice level
Variable Observed prevalence (%) Unadjusted odds ratio (95% CI) Adjusted odds ratio (95% CI)
Age, years
65–70 138/1181 (11.7) 1 (reference) 1 (reference)
71–75 232/2236 (10.4) 0.88 (0.70–1.11) 0.86 (0.68–1.09)
76–80 350/4007 (8.7) 0.73 (0.59–0.91) 0.70 (0.56–0.87)
81–85 448/5764 (7.8) 0.64 (0.52–0.79) 0.61 (0.49–0.75)
[85 712/9453 (7.5) 0.62 (0.51–0.75) 0.58 (0.48–0.71)
Number of medications on repeat prescriptions in the previous 12 months (excluding antipsychotic drugs)
0–5 439/7519 (5.8) 1 (reference) 1 (reference)
6–9 472/6121 (7.7) 1.47 (1.27–1.71) 1.47 (1.27–1.70)
10–14 547/5450 (10.0) 1.94 (1.68–2.25) 1.96 (1.69–2.26)
15 or more 422/3551 (11.9) 2.33 (2.00–2.73) 2.31 (1.98–2.70)
Sex
Male 647/7857 (8.2) 1 (reference) 1 (reference)
Female 1233/14784 (8.3) 1.00 (0.90–1.11) 1.06 (0.95–1.17)
List size (quartiles)
\5000 202/2438 (8.3) 1 (reference) 1 (reference)
5000 to\8000 440/5197 (8.5) 1.06 (0.8–1.38) 0.96 (0.75–1.22)
8000 to\11,000 587/7253 (8.1) 1.04 (0.80–1.35) 0.97 (0.76–1.24)
[11,000 651/7753 (8.4) 1.07 (0.82–1.39) 1.10 (0.86–1.42)
Proportion (%) of patients in practice aged 65 years or over (CPRD mean = 19.6%)
\15 289/3409 (8.5) 1 (reference) 1 (reference)
15 to\20 733/8181 (9.0) 1.14 (0.90–1.45) 1.04 (0.83–1.31)
20 to\25 632/7565 (8.4) 1.06 (0.83–1.36) 0.95 (0.75–1.21)
[25 226/3486 (6.5) 0.84 (0.61–1.15) 0.82 (0.60–1.12)
Practice level index of multiple deprivation
1 least deprived 409/4801 (8.5) 1 (reference) 1 (reference)
2 415/4578 (9.1) 1.07 (0.82 1.40) 1.24 (0.97–1.59)
3 386/4723 (8.2) 0.99 (0.76–1.29) 1.16 (0.90–1.49)
4 371/4767 (7.8) 1.04 (0.80–1.36) 1.09 (0.85–1.40)
5 most deprived 299/3772 (7.9) 0.99 (0.75–1.30) 0.96 (0.73–1.25)
Region
North West 204/2309 (8.8) 1 (reference) 1 (reference)
North East 6/202 (3.0) 0.29 (0.10–0.82) 0.30 (0.11–0.86)
Yorkshire/Humber 15/251 (6.0) 0.69 (0.31–1.53) 0.71 (0.32–1.59)
West Midlands 175/1994 (8.8) 0.96 (0.68–1.35) 1.05 (0.74–1.50)
East of England 126/1380 (9.1) 1.00 (0.69–1.45) 1.06 (0.72–1.56)
South West 110/1888 (5.8) 0.58 (0.40–0.84) 0.61 (0.41–0.90)
South central 203/3270 (6.2) 0.63 (0.46–0.87) 0.64 (0.46–0.90)
London 114/2017 (5.7) 0.57 (0.40–0.80) 0.56 (0.39–0.80)
South East coast 155/2506 (6.2) 0.59 (0.43–0.83) 0.63 (0.45–0.89)
Northern Ireland 166/1137 (14.6) 1.74 (1.20 to 2.53) 1.51 (1.03–2.22)
Scotland 342/3516 (9.7) 1.07 (0.80 to 1.42) 1.14 (0.85–1.53)
Wales 264/2171 (12.2) 1.43 (1.05 to 1.94) 1.55 (1.13–2.11)
CI confidence interval, CPRD Clinical Practice Research Datalink
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prescribing might be expected given that the March 2009
DSU pointed out that risperidone was licenced specifically
for short term (‘up to 6 weeks’) treatment of persistent
aggression in Alzheimer’s dementia, but it should not have
resulted in the observed increased prevalence of repeated
prescribing for 3 months or longer.
The more marked effect of the 2004 CSM warning
compared with the 2009 MHRA DSU has been observed
previously in the UK [24, 26]. As pointed out by these
authors [24, 26], the nature of the warnings might explain
these large differences in effect. The 2004 CSM warning
was sent to all healthcare professionals marked ‘urgent
message’’ and contained explicit and clear guidance on
how prescribers should respond [10], whereas the 2009
MHRA DSU simply recommended caution in initiation
through a limited circulation bulletin [14]. We further
suggest that the impact of the NICE guidance was more
gradual and sustained in its impact, potentially reflecting
different implementation policies and priorities across
NHS trusts and general practices. We had decided a priori
that 6 or 12 months following the warning or guidance was
an appropriate length of time to judge whether or not an
intervention had been effective but it is also important to
look at the longer-term impact of consecutive warnings.
4.2 Variation in Prescribing Patterns
between Practices and Patients
The wide variation in prescribing between practices, even
after adjusting for patient- and practice-level predictors, is
of interest. The reliability of these prescribing safety
indicator prevalence estimates has been discussed in a
previous study; around 80% of the practices have suffi-
cient patients aged over 65 years with a diagnosis of
dementia and without psychosis to allow valid compar-
isons between practices [22]. The lower levels of pre-
scribing to patients aged over 75 years may reflect advice
provided by the Royal College of Psychiatrists to
accompany the 2004 CSM warning that highlighted the
increased risks for older patients [34]. It is not clear why
multi-morbid patients (identified by polypharmacy) are
more likely to be prescribed an antipsychotic drug,
although is likely that the behaviours that would merit the
prescription of an anti-psychotic tend to occur in the later
stages of the illness and therefore the patient may be
receiving prescriptions for other conditions. Another
possibility is that multi-morbid patients may be more
likely to live in residential care facilities where pre-
scribing of antipsychotic drugs has remained high despite
the National Dementia Strategy [35]. The significantly
higher prescribing in Wales and Northern Ireland may be
selection bias resulting from the small number of CPRD
practices from these countries.
4.3 Strengths and Limitations of the Study
In this large comprehensive study of antipsychotic drug
prescribing to patients with dementia, we have considered
‘end of life’ prescribing by excluding patients who died
within the 6 months leading up to the audit date from the
denominator. We also allowed for the clinically appropri-
ate short-term prescribing as described in the NICE
guidelines by only including prescribing occurring for at
least 3 months in the numerator. It is possible that changes
in clinicians’ recording of psychosis diagnoses could
influence our results but our sensitivity analyses showed
that the prevalence ratios describing changes over time
were similar for patients with, or without, a recorded
psychosis diagnosis.
The main limitation is that any hypothesised relationship
between the implementation of guidelines or warnings and
changes in prescribing is based purely on a temporal
association. We have no direct evidence of causation.
Other interventions besides these that we selected for for-
mal evaluation, e.g., the formation of the Dementia Action
Alliance in 2010, may have had an impact [26]. Local
policies might arise in response to the preceding policy
intervention, thus we should consider the changes over a
longer time frame as well as the immediate impacts cap-
tured by the formal ITS analysis. Another potential com-
plicating factor is the introduction of the Quality and
Outcomes Framework, a pay-for-performance programme
introduced in 2004 that rewards general practitioners for
recording and managing certain chronic conditions [36].
Prevalence levels are known to increase after the intro-
duction of a Quality and Outcomes Framework incentive,
[37] and psychosis and dementia were included in the
scheme at different timepoints, in 2004 (as part of severe
mental illness) and 2006, respectively. Nevertheless, our
results are largely unaffected by the inclusion or not of
patients with psychosis, while changes in dementia
prevalence over time are less pertinent to our research
question.
5 Conclusions and Implications for the Future
In 2014, 8.2% of older patients with a diagnosis of dementia
without psychosis were prescribed a second-generation
antipsychotic drug for at least 3 months. Warnings and
guidelines appear to have had a marked, albeit in some cases
short-lived, impact on clinical practice. A further carefully
worded warning may be justified to reduce the longer-term
prescribing of risperidone without precipitating an increase
in the prescribing of other types of antipsychotic drugs (or
sedatives or antidepressants). Given the high variation in
prevalence between practices, a more targeted intervention
S. J. Stocks et al.
may be required, possibly implemented through the numer-
ous computer systems that are active inUKprimary care [38]
or through medication review by clinical pharmacists
working in general practices as endorsed by the NICE
Medicines Optimisation guidance [39]. Prescribing in pri-
mary care can occur at the request of a psychiatrist or it may
be initiated by a general practitioner. Further work could
examine whether prescribing to patients referred to psychi-
atrists differed to those without referral. Nonetheless, it is
important that general practitioners and psychiatrists work
together to address this problem.
In general, the impact of drug safety warnings and
guidelines will depend on multiple factors, [40] yet these
factors are rarely investigated in relation to the type of
intervention and its method of dissemination. Increased
surveillance of the effectiveness of drug safety warnings
and guidance is needed to improve the impact of future
interventions.
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